• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    77 Biggest Movers From Yesterday

    6/1/22 5:02:22 AM ET
    $ACOR
    $AMR
    $ANF
    $ANGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Coal Mining
    Energy
    Get the next $ACOR alert in real time by email

    Gainers

    • TherapeuticsMD, Inc. (NASDAQ:TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners.
    • JanOne Inc. (NASDAQ:JAN) gained 66.5% to close at $3.73 after the company announced it sold GeoTraq to SPYR Technologies in a $13.5 million transaction.
    • Mullen Automotive, Inc. (NASDAQ:MULN) jumped 44.9% to settle at $1.40 after the company announced results of its solid-state polymer battery testing with the Battery Innovation Center in Indiana.
    • Studio City International Holdings Limited (NASDAQ:MSC) gained 43.3% to close at $3.21.
    • CatchMark Timber Trust, Inc. (NYSE:CTT) shares climbed 42.1% to close at $11.79 after the company and PotlatchDeltic announced they have entered into a definitive agreement to combine in an all-stock transaction.
    • Xcel Brands, Inc. (NASDAQ:XELB) gained 36.7% to settle at $1.49 after the company announced WHP will purchase a controlling 70% interest in fashion brand Isaac Mizrahi.
    • DURECT Corporation (NASDAQ:DRRX) jumped 32.1% to settle at $0.55. Durect, last month, posted a Q1 net loss of $10.8 million.
    • ReShape Lifesciences Inc. (NASDAQ:RSLS) surged 28.7% to close at $1.0105.
    • Houston American Energy Corp. (NYSE:HUSA) gained 27.4% to settle at $4.79. Houston American Energy increased interest in the Colombian project. According to Stocktwits, Houston American Energy was the number one trending stock for the day.
    • Stealth BioTherapeutics Corp (NASDAQ:MITO) surged 26.8% to close at $0.2690.
    • mCloud Technologies Corp. (NASDAQ:MCLD) jumped 25.7% to close at $3.77.
    • BlackSky Technology Inc. (NASDAQ:BKSY) surged 24.8% to close at $3.27.
    • Versus Systems Inc. (NASDAQ:VS) jumped 24% to close at $0.63.
    • OpGen, Inc. (NASDAQ:OPGN) gained 23.2% to close at $0.69.
    • Pop Culture Group Co., Ltd (NASDAQ:CPOP) surged 21.9% to settle at $1.28.
    • MoonLake Immunotherapeutics (NASDAQ:MLTX) jumped 21.2% to close at $7.73.
    • RISE Education Cayman Ltd (NASDAQ:REDU) climbed 21.2% to close at $1.37.
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) gained 21.2% to settle at $0.5091.
    • MicroStrategy Incorporated (NASDAQ:MSTR) surged 20.7% to settle at $264.69 in sympathy with the price of Bitcoin and Ethereum.
    • Biotricity, Inc. (NASDAQ:BTCY) gained 20.6% to settle at $1.23.
    • Eargo, Inc. (NASDAQ:EAR) jumped 20.2% to close at $1.55 after Nasdaq confirmed continued listing of the stock.
    • Summit Therapeutics Inc. (NASDAQ:SMMT) gained 19.8% to close at $1.33. Summit Therapeutics, last month, posted a Q1 loss of $0.22 per share.
    • Gogoro Inc. (NASDAQ:GGR) rose 19.3% to close at $5.01.
    • 180 Life Sciences Corp. (NASDAQ:ATNF) jumped 18.3% to settle at $1.62 after the company announced it has initiated preliminary consultations with UK and US regulatory agencies on a pathway for a Dupuytren's disease therapy.
    • Rockwell Medical, Inc. (NASDAQ:RMTI) gained 18% to settle at $1.64. Rockwell Medical entered into securities purchase agreements with Armistice Capital Master Fund Ltd to purchase $15 million of common stock and warrants.
    • Esports Entertainment Group, Inc. (NASDAQ:GMBL) gained 17.7% to close at $0.46. HC Wainwright & Co. maintained Esports Entertainment with a Buy and lowered the price target from $6 to $1.5.
    • Angion Biomedica Corp. (NASDAQ:ANGN) jumped 17.3% to close at $1.76. Angion Biomedica, last month, posted a Q1 loss of $0.48 per share.
    • NexImmune, Inc. (NASDAQ:NEXI) gained 16.9% to settle at $2.28. NexImmune, last month, posted a Q1 loss of $0.66 per share.
    • Skylight Health Group Inc. (NASDAQ:SLHG) jumped 16.9% to close at $0.8301. Skylight Health Group, last month, posted Q1 loss from continuing operations of $7.6 million.
    • Full Truck Alliance Co. Ltd. (NYSE:YMM) climbed 16.7% to close at $6.93.
    • Sesen Bio, Inc. (NASDAQ:SESN) gained 16.7% to close at $0.6129.
    • Sigma Labs, Inc. (NASDAQ:SASI) rose 16.7% to settle at $1.3999.
    • KE Holdings Inc. (NYSE:BEKE) rose 16.6% to settle at $13.40 after the company announced better-than-expected Q1 sales results.
    • Talaris Therapeutics, Inc. (NASDAQ:TALS) gained 16.4% to close at $8.61.
    • Ikena Oncology, Inc. (NASDAQ:IKNA) jumped 16.1% to close at $3.90. Ikena Oncology, last month, posted a Q1 loss of $0.47 per share.
    • Grupo Aval Acciones y Valores S.A. (NYSE:AVAL) gained 16.1% to close at $4.91.
    • WiSA Technologies, Inc. (NASDAQ:WISA) jumped 15.3% to close at $0.8221.
    • Marine Petroleum Trust (NASDAQ:MARPS) rose 13.4% to close at $8.82.
    • Sangoma Technologies Corporation (NASDAQ:SANG) gained 12.9% to settle at $9.31.
    • Performance Shipping Inc. (NASDAQ:PSHG) rose 11.9% to close at $0.7420. Performance Shipping shares dipped around 64% on Friday after the company announced the pricing of an underwritten public offering of 7,620,000 units at $1.05 per unit.
    • Venator Materials PLC (NYSE:VNTR) gained 11.4% to close at $2.54.
    • Pineapple Energy Inc. (NASDAQ:PEGY) climbed 10.7% to close at $13.06. Pineapple Holdings recently posted a Q1 loss of $0.58 per share.
    • Borr Drilling Limited (NYSE:BORR) shares rose 10.7% to settle at $5.57 after the company reported preliminary results for its first quarter.
    • Grab Holdings Limited (NASDAQ:GRAB) gained 10.4% to close at $2.66 after Bernstein upgraded the stock from Market Perform to Outperform.
    • New Oriental Education & Technology Group Inc. (NYSE:EDU) shares climbed 9.6% to close at $13.06.
    • Bakkt Holdings, Inc. (NYSE:BKKT) gained 7.1% to close at $2.85 in sympathy with the price of Bitcoin and Ethereum.
    • Indonesia Energy Corporation Limited (NYSE:INDO) gained 6.4% to close at $16.73 after gaining 6% on Friday.

     


    Losers

    • Icosavax, Inc. (NASDAQ:ICVX) dropped 33.6% to close at $6.79. Icosavax recently posted a Q1 loss of $0.60 per share.
    • Outlook Therapeutics, Inc. (NASDAQ:OTLK) dipped 32% to settle at $1.15. Outlook Therapeutics said that the FDA has requested additional information in order to complete filing of company’s BLA for ONS-5010/ LYTENAVA.
    • PDS Biotechnology Corporation (NASDAQ:PDSB) shares declined 27.1% to close at $3.92. PDS Biotech announced expansion of its Versatile-002 clinical trial into Europe.
    • Elevation Oncology, Inc. (NASDAQ:ELEV) shares fell 25.4% to close at $2.26. Elevation Oncology recently announced the FDA granted Fast Track designation to seribantumab for the tumor-agnostic treatment of advanced solid tumors that harbor NRG1 gene fusions.
    • Gold Fields Limited (NYSE:GFI) fell 23.4% to close at $9.34 on Tuesday after the company announced it will acquire Yamana Gold for $6.7 billion.
    • PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) fell 23.3% to close at $11.76.
    • PropertyGuru Limited (NYSE:PGRU) fell 23% to close at $5.59. PropertyGuru recently reported Q1 sales of S$28.2 million.
    • JE Cleantech Holdings Limited (NASDAQ:JCSE) fell 22.6% to close at $11.60.
    • Innovid Corp. (NYSE:CTV) dropped 22% to close at $3.80.
    • MSP Recovery, Inc. (NASDAQ:MSPR) fell 21.8% to settle at $1.36.
    • Perma-Pipe International Holdings, Inc. (NASDAQ:PPIH) dropped 21.2% to close at $11.73.
    • Immix Biopharma, Inc. (NASDAQ:IMMX) fell 20.2% to close at $2.14.
    • SIGA Technologies, Inc. (NASDAQ:SIGA) dropped 20% to settle at $10.94.
    • Farmmi, Inc. (NASDAQ:FAMI) fell 18.1% to close at $1.27 following effect of 1:25 reverse stock split.
    • Bright Green Corporation (NASDAQ:BGXX) dipped 17.8% to close at $5.08.
    • Myriad Genetics, Inc. (NASDAQ:MYGN) declined 16.8% to settle at $19.24.
    • BioSig Technologies, Inc. (NASDAQ:BSGM) fell 16.3% to close at $0.9874.
    • Lixiang Education Holding Co., Ltd. (NASDAQ:LXEH) dipped 15.6% to settle at $2.82.
    • Frontline Ltd. (NYSE:FRO) shares dropped 15.3% to close at $9.68 after gaining 5% on Friday.
    • LexinFintech Holdings Ltd. (NASDAQ:LX) declined 14.8% to settle at $2.02 after the company reported unaudited results for the first quarter.
    • Kirkland's, Inc. (NASDAQ:KIRK) dropped 14.6% to close at $5.79 as the company reported a first-quarter FY22 sales decline of 16.4% to $103.29 million, missing the consensus of $110.46 million.
    • TG Therapeutics, Inc. (NASDAQ:TGTX) fell 14.5% to close at $4.42. TG Therapeutics announced FDA extension of BLA PDUFA date for ublituximab to treat patients with RMS.
    • Celldex Therapeutics, Inc. (NASDAQ:CLDX) dipped 14.5% to settle at $23.52.
    • BuzzFeed, Inc. (NASDAQ:BZFD) fell 14.4% to close at $3.5950.
    • Purple Innovation, Inc. (NASDAQ:PRPL) dropped 14% to close at $5.18.
    • Evolve Transition Infrastructure LP (NYSE:SNMP) declined 13.8% to close at $0.5690.
    • Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares fell 11.6% to close at $2.21. Needham maintained Avadel Pharmaceuticals with a Buy and lowered the price target from $14 to $6.
    • Alpha Metallurgical Resources, Inc. (NYSE:AMR) dropped 9.8% to close at $161.74.
    • Abercrombie & Fitch Co. (NYSE:ANF) dropped 9.4% to close at $20.44.
    • NetScout Systems, Inc. (NASDAQ:NTCT) declined 8.8% to close at $34.33 after Piper Sandler downgraded the stock from Neutral to Underweight and lowered its price target from $35 to $33.
    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $AMR
    $ANF
    $ANGN

    CompanyDatePrice TargetRatingAnalyst
    Immix Biopharma Inc.
    $IMMX
    2/9/2026$14.00Outperform
    Mizuho
    Alpha Metallurgical Resources Inc.
    $AMR
    2/4/2026$203.00Buy → Neutral
    B. Riley Securities
    KE Holdings Inc
    $BEKE
    2/3/2026$19.00Buy → Neutral
    Goldman
    New Oriental Education & Technology Group Inc. Sponsored ADR r
    $EDU
    1/28/2026Hold → Buy
    HSBC Securities
    Strategy Inc
    $MSTR
    1/27/2026$213.00Overweight
    Cantor Fitzgerald
    Abercrombie & Fitch Company
    $ANF
    1/21/2026$135.00Neutral → Buy
    Citigroup
    Grab Holdings Limited
    $GRAB
    1/16/2026$6.20Hold → Buy
    HSBC Securities
    Full Truck Alliance Co. Ltd.
    $YMM
    1/12/2026Neutral → Underweight
    Analyst
    More analyst ratings

    $ACOR
    $AMR
    $ANF
    $ANGN
    SEC Filings

    View All

    OpGen Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CapForce Inc. (0001293818) (Filer)

    2/27/26 5:29:02 PM ET
    $OPGN
    Medical Specialities
    Health Care

    SEC Form 10-K filed by TG Therapeutics Inc.

    10-K - TG THERAPEUTICS, INC. (0001001316) (Filer)

    2/27/26 5:05:11 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Grupo Aval Acciones y Valores S.A.

    6-K - Grupo Aval Acciones Y Valores S.A. (0001504764) (Filer)

    2/27/26 5:04:28 PM ET
    $AVAL
    Commercial Banks
    Finance

    $ACOR
    $AMR
    $ANF
    $ANGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Immix Biopharma with a new price target

    Mizuho initiated coverage of Immix Biopharma with a rating of Outperform and set a new price target of $14.00

    2/9/26 7:01:42 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alpha Metallurgical Resources downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Alpha Metallurgical Resources from Buy to Neutral and set a new price target of $203.00

    2/4/26 8:27:05 AM ET
    $AMR
    Coal Mining
    Energy

    KE Holdings downgraded by Goldman with a new price target

    Goldman downgraded KE Holdings from Buy to Neutral and set a new price target of $19.00

    2/3/26 6:53:05 AM ET
    $BEKE
    Real Estate
    Finance

    $ACOR
    $AMR
    $ANF
    $ANGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

    12/28/22 12:54:09 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-6) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 12/28/2021. Application Category: NDA, Application Number: 210132, Application Classification: Efficacy

    12/29/21 7:23:57 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AMR
    $ANF
    $ANGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.

    CLARKSBURG, Md., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OpGen, Inc. (OTC:OPGN) today announced that it is changing its name to CapForce Inc., effective today. OpGen changed its name to CapForce Inc. in order to reflect the repositioning of the Company's business to the digital investment banking and financial technology sectors. The name "CapForce" represents the "Force of Capital," symbolizing the Company's conviction as a next-generation category-defining fintech-powered investment bank that harnesses the intrinsic force of capital, through capital markets as the empowerment medium, to empower global mid-sized high growth companies to grow beyond the small-cap universe and punch above their w

    2/27/26 5:30:32 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

    - Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks -- Greatly improved quality of life and reduced disease impact for patients with ColdU/SD at Week 20 -HAMPTON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic dermographism (SD). Barzolvolimab is a humanized monoclonal antibody with a completely novel mechanism of action that uniquely targets the root cause of CSU, ColdU and SD—

    2/27/26 2:45:00 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Bakkt Announces Pricing of $48.125 Million Registered Direct Offering

    NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Bakkt, Inc. ("Bakkt" or the "Company") (NYSE:BKKT) today announced the pricing of a registered direct offering of 3,024,799 shares of Class A common stock and pre-funded warrants to purchase up to 2,475,201 shares of Class A common stock at a price of $8.75 per share and $8.7499 per pre-funded warrant, which represents the per share price of each share of Class A common stock less the $0.0001 per share exercise price for each pre-funded warrant. The offering to a single institutional investor is expected to close on or around March 2, 2026, subject to customary closing conditions. The gross proceeds from the offering, before deducting placement a

    2/27/26 7:32:49 AM ET
    $BKKT
    Finance: Consumer Services
    Finance

    $ACOR
    $AMR
    $ANF
    $ANGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Phanstiel S. Louise bought $494,722 worth of shares (104,507 units at $4.73), increasing direct ownership by 59% to 281,951 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    2/27/26 4:46:18 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Thompson Tommy G bought $14,031 worth of shares (8,400 units at $1.67), increasing direct ownership by 57% to 23,179 units (SEC Form 4)

    4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

    12/29/25 4:23:31 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman D Loren Robert W bought $94,908 worth of shares (81,466 units at $1.17), increasing direct ownership by 13% to 687,297 units (SEC Form 4)

    4 - XCel Brands, Inc. (0001083220) (Issuer)

    12/19/25 12:42:34 PM ET
    $XELB
    Multi-Sector Companies
    Miscellaneous

    $ACOR
    $AMR
    $ANF
    $ANGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel and Secretary D'Annunzio Marc sold $7,924 worth of shares (785 units at $10.09), decreasing direct ownership by 0.66% to 117,833 units (SEC Form 4)

    4 - Bakkt, Inc. (0001820302) (Issuer)

    2/27/26 5:49:38 PM ET
    $BKKT
    Finance: Consumer Services
    Finance

    Director Phanstiel S. Louise bought $494,722 worth of shares (104,507 units at $4.73), increasing direct ownership by 59% to 281,951 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    2/27/26 4:46:18 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Liebman Howard M returned $1,573 worth of shares to the company (777 units at $2.02), decreasing direct ownership by 4% to 19,617 units (SEC Form 4)

    4 - XCel Brands, Inc. (0001083220) (Issuer)

    2/24/26 3:29:50 PM ET
    $XELB
    Multi-Sector Companies
    Miscellaneous

    $ACOR
    $AMR
    $ANF
    $ANGN
    Leadership Updates

    Live Leadership Updates

    View All

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    Bakkt Agrees to Acquire Distributed Technologies Research Ltd.

    - Acquisition advances Bakkt's global stablecoin settlement and programmable payments strategy- Company to operate as "Bakkt, Inc." effective January 22, 2026- Investor Day scheduled for March 17, 2026 at the New York Stock Exchange NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Bakkt Holdings, Inc. ("Bakkt" or the "Company") (NYSE:BKKT) today announced that it has agreed to acquire Distributed Technologies Research Ltd. ("DTR"), a global stablecoin payment infrastructure provider. Pursuant to the definitive agreement, and as consideration for DTR, Bakkt will issue shares of its Class A common stock representing 31.5% of the "Bakkt Share Number," as defined in the previously announced Coope

    1/12/26 8:00:00 AM ET
    $BKKT
    Finance: Consumer Services
    Finance

    Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

    ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. "We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution," said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. "Laura's two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value

    1/6/26 8:35:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AMR
    $ANF
    $ANGN
    Financials

    Live finance-specific insights

    View All

    Alpha Announces Financial Results for Fourth Quarter and Full Year 2025

    Reports net loss of $17.3 million for the fourth quarter 2025 Posts Adjusted EBITDA of $28.5 million for the quarterBRISTOL, Tenn., Feb. 27, 2026 /PRNewswire/ -- Alpha Metallurgical Resources, Inc. (NYSE:AMR), a leading U.S. supplier of metallurgical products for the steel industry, today reported financial results for the fourth quarter and full year ending December 31, 2025. (millions, except per share)Three months endedDec. 31, 2025Sept. 30, 2025Dec. 31, 2024Net loss($17.3)($5.5)($2.1)Net loss per diluted share($1.34)($0.42)($0.16)Adjusted EBITDA(1)$28.5$41.7$53.2Operating ca

    2/27/26 7:30:00 AM ET
    $AMR
    Coal Mining
    Energy

    Full Truck Alliance Co. Ltd. to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Earnings Call Scheduled for 8:00 A.M. U.S. ET on March 12, 2026 GUIYANG, China, Feb. 27, 2026 /PRNewswire/ -- Full Truck Alliance Co. Ltd. ("FTA" or the "Company") (NYSE:YMM), a leading digital freight platform, today announced that it will release its fourth quarter and fiscal year 2025 unaudited financial results on Thursday, March 12, 2026, before the open of the U.S. markets. The Company's management will hold an earnings conference call at 8:00 A.M. U.S. Eastern Time on March 12, 2026 or 8:00 P.M. Beijing Time to discuss the financial results.For participants who wish to join the conference using dial-in numbers, please complete online registration using the link provided below prior to

    2/27/26 3:00:00 AM ET
    $YMM
    Computer Software: Prepackaged Software
    Technology

    BlackSky Reports Fourth Quarter and Full Year 2025 Results

    Delivered Q4 Revenue of $35 Million Q4 Net Loss Narrows with Strong Q4 Adjusted EBITDA Performance Strong Momentum in New Gen-3 Contracts Results in YoY Backlog Growth of 32% to $345 Million BlackSky Technology Inc. ("BlackSky" or the "Company") (NYSE:BKSY) announced results for the fourth quarter and full year ended December 31, 2025. "Growing demand and new Gen-3 contract awards drove a strong Q4 and delivered a second consecutive year of positive adjusted EBITDA," said Brian E. O'Toole, BlackSky CEO. "With the exceptional performance of Gen-3, we're converting early customer pilots into long-term subscription contracts worldwide. Significant international demand drove the majorit

    2/26/26 7:00:00 AM ET
    $BKSY
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ACOR
    $AMR
    $ANF
    $ANGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PMV Pharmaceuticals Inc.

    SC 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    12/12/24 12:29:41 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Full Truck Alliance Co. Ltd.

    SC 13G/A - Full Truck Alliance Co. Ltd. (0001838413) (Subject)

    12/3/24 4:30:33 PM ET
    $YMM
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by DURECT Corporation

    SC 13G/A - DURECT CORP (0001082038) (Subject)

    11/19/24 5:10:25 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AMR
    $ANF
    $ANGN
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

    Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

    6/10/24 1:09:24 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care